Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab  bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639)

Affiliations

Abstract

No abstracts available.

ISSN: 1758-8340 (Print); 1758-8359 (Online)
Publisher: SAGE Publishing
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://journals.sagepub.com/home/tam